Compare Cadence Design Systems Inc (CDNS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cadence Design Systems Inc vs Neurocrine Biosciences Inc — how do they compare? Cadence Design Systems Inc trades at $328.2 (market cap $91.41B), while Neurocrine Biosciences Inc trades at $162.07 (market cap $16.76B). The key difference: Cadence Design Systems Inc is far larger — about 5.5× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Cadence Design Systems Inc nearer its low. Which is the better fit depends on your goals.
| CDNS | NBIX | |
|---|---|---|
Market Cap | $91.41B | $16.76B |
Sector | Technology | Health |
52-Week High | $416.39 | $185.50 |
52-Week Low | $265.66 | $123.10 |
Enterprise Value | $92.62B | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cadence Design Systems (CDNS) trades at $339.24, up 0.24% on the day, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.11 surpassing expectations. Revenue growth is robust, driven by AI demand, with 2025 revenue reaching $5.30 billion and a net income margin of 23.61%. Analyst sentiment is overwhelmingly positive, with 83.87% recommending Buy and a consensus price target of $415.11.
The outlook for CDNS is favorable, supported by strong AI-driven demand, record backlog of $8.1 billion as of Q2 2026 (Zacks Investment Research, 2026-07-30), and upwardly revised guidance. Risks include high valuation multiples, such as a P/E of 67.44, and potential market volatility amid semiconductor sector fluctuations. Institutional confidence remains high, with Amundi increasing its stake by 3.8% in Q1 2026 (Defense World, 2026-07-30).
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
